Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$57.94 USD
+0.31 (0.54%)
Updated Feb 6, 2025 04:00 PM ET
After-Market: $57.93 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
02/18/2025
Time: AMC |
12/2024 | $1.16 | 0.00% |
Earnings Summary
For their last quarter, Halozyme Therapeutics (HALO) reported earnings of $1.27 per share, beating the Zacks Consensus Estimate of $0.99 per share. This reflects a positive earnings surprise of 28.28%. Look out for HALO's next earnings release on February 18, 2025. For the next earning release, we expect the company to report earnings of $1.16 per share, reflecting a year-over-year increase of 41.46%.
Earnings History
Price & Consensus
Zacks News for HALO
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
HALO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
HALO FAQs
Halozyme Therapeutics, Inc. (HALO) has announced they will report their next quarter earnings on February 18, 2025. For the next earning release, we expect the company to report earnings of $1.16 per share, reflecting a year-over-year increase of 41.46%.
Halozyme Therapeutics, Inc. has announced they will report their previous quarter earnings after the close of the market on February 18, 2025.
The Zacks Consensus Estimate for Halozyme Therapeutics, Inc. (HALO) for the quarter ending December 2024 is $1.16 a share. We expect Halozyme Therapeutics, Inc. (HALO) to report earnings in line with the consensus estimate of $1.16 per share
In the earnings report for the quarter ending in September 2024, Halozyme Therapeutics, Inc. (HALO) announced earnings of $1.27 per share versus the Zacks Consensus Estimate of $0.99 per share, representing a surprise of 28.28%.